Comparison of PD‐L1 detection assays and corresponding significance in evaluation of diffuse large B‐cell lymphoma

The expression of programmed cell death ligand 1 (PD‐L1) is a biomarker for immunotherapy, but approved detection method is absent in diffuse large B‐cell lymphoma (DLBCL). Here, we performed three methods including immunohistochemistry (IHC) (clone SP263 and SP142), RNAscope, and fluorescence in situ hybridization (FISH) to evaluate PD‐L1 status on a cohort of DLBCL including 94 of DLBCL‐NOS, 25 of primary mediastinal large B‐cell lymphoma (PMBCL) and 7 of double‐hit lymphoma (DHL). SP263 with 25% for immune cell (IC) or combined cell and SP142 with 10% for tumor cell (TC), 20% for both of IC and combined cell were proved to have corresponding survival prognostic. Combined+ showed comparable prognostic value with TC+ and IC+. SP263 and SP142 showed strong concordance (k = 0.788) with combined+ rates of 33.3% (42/126) and 34.9% (44/126), respectively. In DLBCL‐NOS, TC+ by SP263 preferred to non‐GCB and immunoblastic variant DLBCL‐NOS (P = 0.029 and P = 0.004). Combined+ (SP263 and SP142) were associated with more than one extranodal site involved (P = 0.006, P = 0.042), higher ECOG PS scores (P = 0.001, P < 0.001), high IPI risk (P = 0.012, P = 0.005), and poor treatment response (P = 0.095, P = 0.002). IC+ by SP263 and SP142 were both independent risk factors (P = 0.027, P = 0.037). 9p24.1 locus amplification and gain were identified in 4.3% and 7.6% DLBCL‐NOS and indicated shorter overall survival (P = 0.004). Positive rate of PD‐L1 by RNAscope was 36.5%, while no clinical significance shown. PD‐L1 positive rates were all higher in PMBCL and DHL than in DLBCL‐NOS by SP263, SP142, RNAscope, and FISH (P = 0.001, P < 0.001, P = 0.005 and P < 0.001, respectively). In conclusion, combined PD‐L1 expression by IHC was potentially reliable and convenient as a predicting biomarker. SP263 staining was easier to evaluate and recognized more PD‐L1‐stained cells, but SP142 presented a better prognostic indicator. FISH and RNAscope could be used as supplementary assays. PMBCL itself was a sensitive cohort for immunotherapy.

[1]  Xiaoyan Zhou,et al.  Integrative analysis of PD‐L1 DNA status, mRNA status and protein status, and their clinicopathological correlation, in diffuse large B‐cell lymphoma , 2019, Histopathology.

[2]  J. Winter,et al.  Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL , 2019, Cancer Immunology Research.

[3]  J. Lunceford,et al.  Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer. , 2018, Archives of pathology & laboratory medicine.

[4]  J. Sicklick,et al.  Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors , 2018, JAMA oncology.

[5]  T. Mok,et al.  Assessment of programmed cell death ligand-1 expression by 4 diagnostic assays and its clinicopathological correlation in a large cohort of surgical resected non-small cell lung carcinoma , 2018, Modern Pathology.

[6]  S. Swerdlow.  WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .

[7]  P. Stephens,et al.  Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers , 2017, Molecular Cancer Therapeutics.

[8]  Shuhang Wang,et al.  Clinical applications of PD-L1 bioassays for cancer immunotherapy , 2017, Journal of Hematology & Oncology.

[9]  J. Chavez,et al.  The role of anti-PD-1 and anti-PD-L1 agents in the treatment of diffuse large B-cell lymphoma: The future is now. , 2017, Critical reviews in oncology/hematology.

[10]  E. Hsueh,et al.  Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response , 2017, Biomarker Research.

[11]  F. Hirsch,et al.  PD‐L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD‐L1 IHC Assay Comparison Project , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  Jinghui Wang,et al.  The significance of programmed cell death ligand 1 expression in resected lung adenocarcinoma , 2017, Oncotarget.

[13]  T. Anagnostou,et al.  The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation , 2016, Front. Immunol..

[14]  M. Tiemann,et al.  Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas , 2016, Modern Pathology.

[15]  Kui Wu,et al.  Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas. , 2016, Blood.

[16]  Tianhong Li,et al.  Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy , 2016, Journal of Hematology & Oncology.

[17]  Satoru Miyano,et al.  Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers , 2016, Nature.

[18]  R. Advani,et al.  The World Health Organization Classification of Lymphoid Neoplasms , 2013 .

[19]  J. Zhang,et al.  Programmed death-ligand-1 expression in advanced gastric cancer detected with RNA in situ hybridization and its clinical significance , 2016, Oncotarget.

[20]  E. Jordanova,et al.  Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix , 2016, Modern Pathology.

[21]  Andrew J. Dunford,et al.  Targetable genetic features of primary testicular and primary central nervous system lymphomas. , 2014, Blood.

[22]  K. Akashi,et al.  Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. , 2015, Blood.

[23]  Bert Vogelstein,et al.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.

[24]  E. Hawkes,et al.  Programmed cell death-1 inhibition in lymphoma. , 2015, The Lancet. Oncology.

[25]  Laura Pasqualucci,et al.  The genetic landscape of diffuse large B-cell lymphoma. , 2015, Seminars in hematology.

[26]  Razelle Kurzrock,et al.  PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy , 2015, Molecular Cancer Therapeutics.

[27]  Roman K. Thomas,et al.  PD-L1 expression in small cell neuroendocrine carcinomas. , 2015, European journal of cancer.

[28]  Anne E Carpenter,et al.  Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma , 2014, Oncotarget.

[29]  R. Gascoyne,et al.  Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. , 2013, Blood.

[30]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[31]  Michael R. Green,et al.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. , 2010, Blood.

[32]  B. Coiffier,et al.  Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. , 2010, Blood.

[33]  L. Staudt,et al.  Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma , 2003, The Journal of experimental medicine.

[34]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.